As of June 13, 2025, MabCure Inc (MBCI) reports a Net Margin of -2452.97%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Comparing MabCure Inc's Net Margin to Peers
To better understand MabCure Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| MabCure Inc (MBCI) | -2452.97% |
| HST Global Inc (HSTC) | -6.47% |
| FluoroPharma Medical Inc (FPMI) | -11.76% |
| Protide Pharmaceuticals Inc (PPMD) | -19.25% |
| Gossamer Bio Inc (GOSS) | -49.28% |
| Caladrius Biosciences Inc (CLBS) | -359.67% |
Compared to its competitors, MabCure Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.